Lipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint

Shares of Lipocine plunged about 78% after topline results from its Phase 3 placebo-controlled trial of LPCN-1154 (oral brexanolone) failed to meet the primary endpoint. The clear clinical failure sharply reduces approval and commercial prospects, likely impairing valuation and increasing near-term financing or restructuring risk. This is a company-specific, high-impact event that will drive continued volatility and downside pressure on the stock.

Analysis

Shares of Lipocine plunged about 78% after topline results from its Phase 3 placebo-controlled trial of LPCN-1154 (oral brexanolone) failed to meet the primary endpoint. The clear clinical failure sharply reduces approval and commercial prospects, likely impairing valuation and increasing near-term financing or restructuring risk. This is a company-specific, high-impact event that will drive continued volatility and downside pressure on the stock.